Table 5.
OR (95%CI) | p | aOR (95%CI) | p | |
---|---|---|---|---|
Male vs Female | 0.19 (0.04–0.94) | 0.042 | 0.27 (0.06–1.30) | 0.102 |
Age (× 1 year more) | 0.96 (0.88–1.04) | 0.293 | – | |
MSM vs HE | 0.24 (0.01–4.51) | 0.338 | – | |
IVDUs vs HE | 2.20 (0.58–8.41) | 0.247 | – | |
Other vs HE | 1.36 (0.06–29.16) | 0.844 | – | |
Caucasian vs Non-Caucasian | 0.67 (0.08–5.64) | 0.714 | – | |
BMI (× 1 more) | 0.70 (0.51–0.94) | 0.020 | 0.72 (0.52–1.00) | 0.050 |
Previous AIDS | 0.67 (0.08–5.56) | 0.713 | – | |
Previous therapy duration (× 1 year more) | 1.05 (0.90–1.23) | 0.518 | – | |
CD4 200–500 cell/μL vs < 200 cell/μL | 1.17 (0.05–25.7) | 0.920 | 1.51 (0.07–32.23) | 0.790 |
CD4 > 500 cell/μL vs < 200 cell/μL | 3.97 (0.21–74.51) | 0.357 | 8.12 (0.42–156.90) | 0.166 |
HIV-RNA (× 1 log10 more) | 0.80 (0.54–1.18) | 0.260 | – | |
AST (× 1 more) | 1.02 (1.01–1.03) | 0.008 | 1.01 (0.99–1.03) | 0.144 |
ALT (× 1 more) | 1.01 (1.00–1.02) | 0.015 | – | |
HCV coinfection | 6.93 (1.38–34.87) | 0.019 | 8.00 (1.27–50.29) | 0.027 |
HBV coinfection | 2.39 (0.28–20.36) | 0.427 | – | |
ARV Backbone: AZT/DDI/D4T vs ABC | 0.73 (0.12–4.47) | 0.731 | – | |
ARV Backbone: TDF vs ABC | 0.12 (0.01–3.141) | 0.204 | – | |
ARV Backbone: Other vs ABC | 0.49 (0.02–13.47) | 0.672 | – | |
ABCB1 rs1045642 CT/TT vs CC | 0.18 (0.04–0.76) | 0.020 | 0.10 (0.02–0.47) | 0.004 |
Abbreviations: OR Odds Ratio, aOR adjusted Odds Ratio, CI confidence interval, HE Heterosexual, MSM Man how have sex with man, IVDUs Intra venous drug users, BMI Body Mass Index, cps copies, ABC abacavir, TDF tenofovir diproxil fumarate, BMI Body Mass Index, ABCB ATP Binding Cassette Subfamily B